Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The HTS facility provides Oxford research scientists and collaborators access to a comprehensive, cost-effective facility for running high throughput cell based small compound, RNAi and CRISPR screens across a broad range of readouts.

The HTS team of researchers is lead by Associate Professor Daniel Ebner. Major investment in the group has enabled the procurement of high end, state-of-the-art screening equipment; consisting of liquid handling automation, multiplatform plate readers and high content imaging equipment. This investment results in a facility which is able to produce highly complex and diverse screens.

The aim of our high throughput screening facility at the Target Discovery Institute is to provide collaborative research scientists' access to a comprehensive, cost-effective facility capable of running high throughput biochemical or cell based assays, across small compound and RNAi screening platforms.

A broad range of screens have been run in our facility and our scientists have extensive knowledge of all aspects of high throughput screening. The centre collaborates closely with each researcher and we are available for consultation from the earliest stages of assay conception. We will work closely with each investigator through all stages of assay development, optimization and screening. Diverse drug set libraries totaling several thousand compounds and siRNA screening sets are currently available in house for screening.

Our team